Abstract:The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic continues to spread globally. The rapid dispersion of coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 drives an urgent need for effective treatments, especially for patients who develop severe pneumonia. The excessive and uncontrolled release of pro-inflammatory cytokines has proved to be an essential factor in the rapidity of disease progression, and some cytokines are significantly associated with adverse outcomes. Most of the upregulated cytokines signal through the Janus kinase–signal transducer and activator of transcription (JAK/STAT) pathway. Therefore, blocking the exaggerated release of cytokines, including IL-2, IL-6, TNF-α, and IFNα/β/γ, by inhibiting JAK/STAT signaling will, presumably, offer favorable pharmacodynamics and present an attractive prospect. JAK inhibitors (JAKi) can also inhibit members of the numb-associated kinase (NAK) family, including AP2-associated kinase 1 (AAK1) and cyclin G-associated kinase (GAK), which regulate the angiotensin-converting enzyme 2 (ACE-2) transmembrane protein and are involved in host viral endocytosis. According to the data released from current clinical trials, JAKi treatment can effectively control the dysregulated cytokine storm and improve clinical outcomes regarding mortality, ICU admission, and discharge. There are still some concerns surrounding thromboembolic events, opportunistic infection such as herpes zoster virus reactivation, and repression of the host's type-I IFN-dependent immune repair for both viral and bacterial infection. However, the current JAKi clinical trials of COVID-19 raised no new safety concerns except a slightly increased risk of herpes virus infection. In the updated WHO guideline, Baricitinb is strongly recommended as an alternative to IL-6 receptor blockers, particularly in combination with corticosteroids, in patients with severe or critical COVID-19. Future studies will explore the application of JAKi to COVID-19 treatment in greater detail, such as the optimal timing and course of JAKi treatment, individualized medication strategies based on pharmacogenomics, and the effect of combined medications.

JAK-STAT Signaling As an ARDS Therapeutic Target: Status and Future Trends

Signaling pathways and potential therapeutic targets in acute respiratory distress syndrome (ARDS)

Progress in cytokine research for ARDS: A comprehensive review

Therapeutic Targeting of Interleukin-6 for the Treatment of COVID-19.

Acute Respiratory Distress Syndrome and COVID-19: A Literature Review

Mechanism of COVID-19 Causing ARDS: Exploring the Possibility of Preventing and Treating SARS-CoV-2

Acute respiratory distress syndrome: potential of therapeutic interventions effective in treating progression from COVID-19 to treat progression from other illnesses-a systematic review

Emerging pharmacological therapies for ARDS: COVID-19 and beyond

Targeting JAK-STAT Signaling to Control Cytokine Release Syndrome in COVID-19

JAK Inhibition as a New Treatment Strategy for Patients with COVID-19

Acute Respiratory Distress Syndrome: Bench-to-Bedside Approaches to Improve Drug Development.

JAK-STAT Pathway Inhibition and their Implications in COVID-19 Therapy

Investigational pharmacological agents for the treatment of ARDS

Using the sympathetic system, beta blockers and alpha-2 agonists, to address acute respiratory distress syndrome

Acute Respiratory Distress Syndrome: Bench‐to‐Bedside Approaches to Improve Drug Development

Advancing precision medicine for acute respiratory distress syndrome

Nanomedicine for acute respiratory distress syndrome: The latest application, targeting strategy, and rational design

Novel Biomarkers for Acute Respiratory Distress Syndrome: Genetics, Epigenetics and Transcriptomics

Using a targeted metabolomics approach to explore differences in ARDS associated with COVID-19 compared to ARDS caused by H1N1 influenza and bacterial pneumonia

Efficacy and safety of several common drugs in the treatment of acute respiratory distress syndrome: A systematic review and network meta-analysis

Renin–Angiotensin System: An Important Player in the Pathogenesis of Acute Respiratory Distress Syndrome